Weaponizing T-cell receptors through molecular engineering

Leonard, Elissa K.; Leff, Michael I.; Spangler, Jamie B.

doi:10.1074/jbc.h119.008479

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the aforementioned strategies, novel immunotherapeutics are being developed to complement or replace conventional cell therapy such as soluble TCRs acting as antibody-like reagents [89,90], soluble TCR-antibody fusion proteins binding to infected cells and predisposing them to immune clearance [91,92], or injectable nanocarriers that deliver in vitro-transcribed CAR or TCR mRNA for transient reprograming of circulating T cells to recognize disease-relevant antigens [93 ▪▪ ].…”

Section: Text Of Reviewmentioning

confidence: 99%

Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients

Walti

Stuehler

Palianina

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Double-stranded DNA (dsDNA) viruses remain important causes of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). As treatment options are limited, adoptive therapy with virusspecific T cells (VST) is promising in restoring immunity and thereby preventing and treating virus infections. Here we review current evidence and recent advances in the field of VST for dsDNA viruses in allogeneic HCT recipients. Recent findingsFour different protocols for VST generation are currently used in clinical trials, and various products including multivirus-specific and off-the-shelf products are under investigation for prophylaxis, preemptive therapy or treatment. Data from nearly 1400 dsDNA-VST applications in allogeneic HCT patients have been published and demonstrated its safety. Although Epstein--Barr virus, cytomegalovirus, and adenovirusspecific T-cell therapy studies have predominated over the past 25 years, additional human herpes viruses were added to multivirus-specific T cells over the last decade and clinical evidence for polyomavirus-specific VST has just recently emerged. Response rates of around 70--80% have been reported, but cautious interpretation is warranted as data are predominantly from phase 1/2 studies and clinical efficacy needs to be confirmed in phase 3 studies.

show abstract

Section: Text Of Reviewmentioning

confidence: 99%

Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients

Walti

Stuehler

Palianina

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Moreover, they can replace the CMV antigenemia assay to diagnose infection status in transplant recipients or monitor CMV presentation after vaccination. 70 , 71 …”

Section: ‐Specific Engineered T Cellsmentioning

confidence: 99%

Immunotherapy with adoptive cytomegalovirus‐specific T cells transfer: Summarizing latest gene engineering techniques

Mehdizadeh

Karami

Nazari

et al. 2021

Health Science Reports

View full text Add to dashboard Cite

Cytomegalovirus (CMV) infection remains a major complication following allogeneic hematopoietic stem cell transplantation (HSCT). T cell response plays a critical role in inducing long‐term immunity against CMV infection/reactivation that impairs during HSCT. Adoptive T cell therapy (ACT) via transferring CMV‐specific T cells from a seropositive donor to the recipient can accelerate virus‐specific immune reconstitution. ACT, as an alternative approach, can restore protective antiviral T cell immunity in patients. Different manufacturing protocols have been introduced to isolate and expand specific T cells for the ACT clinical setting. Nevertheless, HLA restriction, long‐term manufacturing process, risk of alloreactivity, and CMV seropositive donor availability have limited ACT broad applicability. Genetic engineering has developed new strategies to produce TCR‐modified T cells for diagnosis, prevention, and treatment of infectious disease. In this review, we presented current strategies required for ACT in posttransplant CMV infection. We also introduced novel gene‐modified T cell discoveries in the context of ACT for CMV infection. It seems that these innovations are enabling to improvement and development of ACT utilization to combat posttransplant CMV infection.

show abstract

Weaponizing T-cell receptors through molecular engineering

Cited by 2 publications

References 10 publications

Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients

Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients

Immunotherapy with adoptive cytomegalovirus‐specific T cells transfer: Summarizing latest gene engineering techniques

Contact Info

Product

Resources

About